Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).
Ravindra Uppaluri(Brigham and Women's Hospital), Douglas R. Adkins(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Rebecca D. Chernock(Washington University in St. Louis), Sidharth V. Puram(Washington University in St. Louis), Ann Marie Egloff(Brigham and Women's Hospital), Dorina Kallogjeri(Washington University in St. Louis), Laura A. Goguen(Brigham and Women's Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Patrik Pipkorn(Washington University in St. Louis), Donald J. Annino(Harvard University), José P. Zevallos(University of Pittsburgh Medical Center), Lara Dunn(Memorial Sloan Kettering Cancer Center), Randal C. Paniello, Mena Mansour(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Jessica Ley(Washington University in St. Louis), Luc G.T. Morris(Memorial Sloan Kettering Cancer Center), Ryan S. Jackson(Washington University in St. Louis)
Cited by 40
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k